Aligos Therapeutics (ALGS) AI Stock Analysis

• Market Cap: $44.35M
• Dividend Yield: N/A
• Average Volume (3M): 86.97K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.68
• Revenue Growth: -55.88%
• EPS Growth: 6.14%
• Country: US
• Employees: 70
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -3.04
• Shares Outstanding: 5,351,374
• 10 Day Avg. Volume: 122,947
• 30 Day Avg. Volume: 86,969
• PEG Ratio: >-0.01
• Price to Book (P/B): -8.61
• Price to Sales (P/S): 63.27
• P/FCF Ratio: -3.09
• Enterprise Value/Market Cap: -0.94
• Enterprise Value/Revenue: -15.70
• Enterprise Value/Gross Profit: -17.40
• Enterprise Value/Ebitda: 0.49
• 1Y Price Target: $112.50
• Price Target Upside: 1040.97% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 39 Underperform
• Price Target: $8.50 ▼(-13.79% Downside)

Aligos Therapeutics' stock score is primarily impacted by its poor financial performance, characterized by declining revenues and persistent losses. The technical analysis suggests bearish momentum, and the valuation metrics indicate significant risks due to negative earnings. These factors collectively result in a low overall stock score.

Positive Factors

Positive Clinical Data

The positive clinical data on pevifoscorvir sodium indicates promising therapeutic potential, enhancing Aligos's competitive position in liver disease treatment.

Pipeline Progress

Successful enrollment in the Phase 2 study suggests robust pipeline progress, which is crucial for long-term growth and potential future revenue streams.

Low Leverage

Maintaining low leverage provides financial flexibility, allowing Aligos to invest in R&D and strategic initiatives without significant debt burden.

Negative Factors

Negative Cash Flow

Negative cash flow indicates potential liquidity issues, limiting the company's ability to fund operations and invest in growth without external financing.

Declining Revenue

Declining revenue growth reflects challenges in market penetration and sales, which could hinder long-term financial health and operational sustainability.

Consistent Losses

Ongoing losses highlight operational inefficiencies and profitability challenges, which may impact the company's ability to achieve financial stability.

Aligos Therapeutics Business Overview & Revenue Model

Company Description

Aligos Therapeutics (ALGS) is a biotechnology company focused on developing innovative therapies for viral infections and liver diseases. The company primarily operates in the biopharmaceutical sector, with a particular emphasis on hepatitis B and other liver-related conditions. Aligos is known for its proprietary technology platforms that facilitate the discovery and development of novel therapeutics aimed at addressing unmet medical needs in these areas.

How the Company Makes Money

Aligos Therapeutics generates revenue through several key streams. Primarily, the company engages in research and development collaborations with larger pharmaceutical companies, which may include upfront payments, milestone payments based on the achievement of specific clinical or regulatory objectives, and royalties on future sales of products developed from these partnerships. Additionally, Aligos may receive funding from government grants or awards aimed at supporting innovative research in the biotech space. The company may also generate revenue through the licensing of its proprietary technologies or drug candidates to other firms in exchange for fees and royalties, enhancing its financial stability and growth prospects.

Aligos Therapeutics Financial Statement Overview

Summary

Aligos Therapeutics faces significant financial challenges, with declining revenues, persistent losses, and negative cash flows. While the company maintains low leverage, its inability to generate profits and positive cash flow raises concerns about its financial sustainability.

Income Statement

Aligos Therapeutics shows a declining revenue trend with a negative revenue growth rate of -16.64% in the TTM. The company has consistently negative net profit margins, indicating ongoing losses. The EBIT and EBITDA margins are also negative, reflecting operational inefficiencies. Overall, the income statement highlights significant challenges in achieving profitability.

Balance Sheet

The balance sheet shows a relatively low debt-to-equity ratio of 0.08 in the TTM, indicating low leverage. However, the return on equity is negative, reflecting the company's inability to generate profits from its equity base. The equity ratio is not explicitly calculated, but the available data suggests a moderate level of equity relative to total assets.

Cash Flow

The cash flow statement reveals a slight improvement in free cash flow growth at 5.87% in the TTM, but operating cash flow remains negative, indicating cash burn. The free cash flow to net income ratio is slightly above 1, suggesting that free cash flow is marginally better than net income, but overall cash flow health is weak.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.65M	3.94M	15.53M	13.91M	4.36M	0.00
Gross Profit	2.39M	3.94M	15.53M	13.91M	4.36M	-3.33M
EBITDA	-84.83M	-86.53M	-85.06M	-93.91M	-124.54M	-105.06M
Net Income	-86.46M	-131.21M	-87.68M	-96.05M	-128.33M	-108.54M
Balance Sheet
Total Assets	109.76M	70.09M	151.53M	146.69M	235.37M	265.30M
Cash, Cash Equivalents and Short-Term Investments	99.10M	56.94M	135.70M	125.83M	190.73M	243.51M
Total Debt	6.07M	8.38M	11.14M	12.57M	14.46M	13.01M
Total Liabilities	37.93M	99.07M	59.45M	42.79M	50.64M	45.26M
Stockholders Equity	71.83M	-28.97M	92.08M	103.90M	184.73M	220.04M
Cash Flow
Free Cash Flow	-79.53M	-80.87M	-79.02M	-80.33M	-116.55M	-76.33M
Operating Cash Flow	-79.16M	-80.74M	-79.00M	-79.39M	-115.66M	-74.26M
Investing Cash Flow	-15.83M	-18.28M	44.98M	-26.29M	3.02M	32.76M
Financing Cash Flow	101.61M	355.00K	88.33M	164.00K	78.68M	192.35M

Aligos Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 9.86
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ALGS, the sentiment is Positive. The current price of 9.86 is above the 20-day moving average (MA) of 7.82, above the 50-day MA of 9.03, and above the 200-day MA of 8.91, indicating a bullish trend. The MACD of 0.18 indicates Negative momentum. The RSI at 61.57 is Neutral, neither overbought nor oversold. The STOCH value of 92.49 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ALGS.

Aligos Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BRNS	42 Neutral	$31.60M	―	-62.30%	―	-100.00%	-26.30%
CELU	40 Underperform	$45.91M	-0.54	―	―	-15.81%	-113.06%
ALGS	39 Underperform	$44.35M	-0.36	-141.82%	―	-55.88%	6.14%
ACRV	36 Underperform	$74.47M	―	-50.23%	―	―	21.17%

Aligos Therapeutics Corporate Events

Aligos Therapeutics Reports Q3 2025 Progress and Financials

Aligos Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for liver and viral diseases, leveraging its scientific expertise to address unmet medical needs such as chronic hepatitis B virus infection and metabolic dysfunction-associated steatohepatitis.

Aligos Therapeutics’ Promising Hepatitis B Study: A Potential Game-Changer?

Study Overview: Aligos Therapeutics, Inc. is conducting a Phase 2 study titled ‘A Study Evaluating the Efficacy and Safety of ALG-000184 Compared With Tenofovir Disoproxil Fumarate in Untreated HBeAg-Positive and HBeAg-Negative Adult Subjects With Chronic Hepatitis B (B-SUPREME)’. The study aims to assess the efficacy and safety of ALG-000184, a potential new treatment for chronic Hepatitis B, compared to the existing treatment, Tenofovir Disoproxil Fumarate (TDF). This study is significant as it could lead to improved treatment options for patients with chronic Hepatitis B.